Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Símbolo de cotizaciónBBLG
Nombre de la empresaBone Biologics Corp
Fecha de salida a bolsaNov 27, 2015
Fundada en2007
Director ejecutivoMr. Jeffrey Frelick
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 27
Dirección2 Burlington Woods Dr Ste 100
CiudadBURLINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal01803-4551
Teléfono17815524452
Sitio Webhttps://www.bonebiologics.com/
Símbolo de cotizaciónBBLG
Fecha de salida a bolsaNov 27, 2015
Fundada en2007
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos